BG
CLCD

BlackRock Group’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

BlackRock Group’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$44K Buy
+1,206
New +$42.7K ﹤0.01% 2923

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock Group's CLCD Position: Q4 2016 in Review

BlackRock Group opened a new position in CoLucid Pharmaceuticals, Inc. (CLCD) in Q4 2016: 1,206 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #2923 among its holdings.

76 funds tracked by Wall St. Rank hold CLCD as of Q4 2016.

  • BlackRock Group held 1,206 shares of CoLucid Pharmaceuticals, Inc. worth $44K as of Q4 2016.
  • CoLucid Pharmaceuticals, Inc. was a new BlackRock Group position in Q4 2016.
  • CoLucid Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2923 holding.
  • 76 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.